Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114084 | 0.79 | MEN1 (0.43) | MEN1KMT2AL3MBTL1GPR84NNMT | |
| SCHEMBL4071509 | 0.75 | — | — | |
| SCHEMBL5106793 | 0.75 | KMT2A (0.38) | MEN1KMT2ALMNA | |
| SCHEMBL29618255 | 0.72 | MEN1 (0.68) | MEN1KMT2AL3MBTL1GPR84NNMT | |
| SCHEMBL128526 | 0.72 | MEN1 (0.68) | MEN1KMT2AL3MBTL1GPR84NNMT | |
| SCHEMBL176636 | 0.69 | MAPT (0.48) | L3MBTL1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10769055 | 0.68 | MEN1 (0.40) | MEN1KMT2AL3MBTL1GPR84ABL1 | |
| SCHEMBL10769061 | 0.68 | MEN1 (0.40) | MEN1KMT2AL3MBTL1GPR84ABL1 | |
| SCHEMBL4120256 | 0.66 | MEN1 (0.58) | MEN1KMT2AL3MBTL1GPR84NNMT | |
| SCHEMBL2488102 | 0.66 | KMT2A (0.44) | MEN1KMT2AL3MBTL1GPR84NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | KCNA3, KCNQ3, GPR3 | MEN1 1842/4885KMT2A 699/4885L3MBTL1 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.